Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
C

How I Treat HL in 2020: What Is the Role of PET-Adapted Strategies? Is BV Superior to Immune CPIs in R/R Disease?

By 7th Eurasian Hematology Oncology Summit FEATURING Christian Gisselbrecht
By 7th Eurasian Hematology Oncology Summit FEATURING Christian Gisselbrecht
0 views
September 30, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
Lymphoma
14:50
7th Eurasian Hematology Oncology Summit

How I Treat Follicular Lymphoma in 2020: Rituximab vs. WW Strategy, …

Feat. G. Gaidano
19:51
7th Eurasian Hematology Oncology Summit

How I Treat DLBCL in 2020: Can Radiotherapy Be Omitted in PET Era? I…

Feat. U. Vitolo
23:29
7th Eurasian Hematology Oncology Summit

2020 Update on IO in R/R cHL: Is Long-Term Therapy w/ Nivo Feasible …

Feat. T. Tuglular
15:27
7th Eurasian Hematology Oncology Summit

How I Treat HL in 2020: What Is the Role of PET-Adapted Strategies? …

Feat. C. Gisselbrecht
21:20
7th Eurasian Hematology Oncology Summit

How I Treat Mantle Cell Lymphoma in 2020: Induction Options, ASCT, a…

Feat. C. Schiffer